Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pasithea Therapeutics Corp ( (KTTA) ) has shared an announcement.
Pasithea Therapeutics Corp. announced that it has regained compliance with Nasdaq’s minimum bid price requirement. The company had been notified on June 23, 2025, about its non-compliance with the $1.00 minimum bid price rule and was given until December 22, 2025, to rectify the situation. As of December 12, 2025, Pasithea’s stock maintained a closing bid price at or above $1.00 per share for a sufficient number of consecutive business days, leading Nasdaq to close the matter.
The most recent analyst rating on (KTTA) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Pasithea Therapeutics Corp stock, see the KTTA Stock Forecast page.
More about Pasithea Therapeutics Corp
Average Trading Volume: 6,925,447
Technical Sentiment Signal: Hold
Current Market Cap: $25.31M
For detailed information about KTTA stock, go to TipRanks’ Stock Analysis page.